Publication: Neisseria Meningitidis Serogrupo B. Análisis fármaco-económico de la vacuna Bexsero®.
Loading...
Official URL
Full text at PDC
Publication Date
2017-02
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La meningitis B es una grave enfermedad provocada por la bacteria N. meningitidis serogrupo B que se transmite de persona a persona mediante las secreciones respiratorias. Se puede ver afectada la nasofaringe o diseminarse y producir la muerte en un corto periodo de tiempo. Se estima que el 10% de la población mundial es portadora asintomática de la bacteria, pero tan solo el 1% progresa hacia la enfermedad invasora. La incidencia de meningitis se ha visto notablemente disminuida, en parte gracias a la vacuna conjugada para el serogrupo C. Desde el año 2013 se comercializa una nueva vacuna de cuatro componentes, Bexsero® y en este trabajo se ha querido analizar el costeeficacia de la vacuna en España, los principales motivos para que ésta no sea financiada y la problemática creada por la alarma social y la falta de suministro en las oficinas de farmacia. Tras la revisión bibliográfica de estudios basados en diferentes países de la Unión Europea se ha llegado a las conclusiones de que los datos europeos no son extrapolables a España, ya que las cepas del meningococo españolas son más parecidas a las de América del Sur. Pero además, la alarma social creada no estaría justificada, ya que aún no hay evidencia de la eficacia de la inmunidad de grupo, pero sí que se garantiza la disponibilidad de vacunas necesarias para situaciones de alto riesgo o brotes.
Meningitis B is a severe disease caused by N. meningitids serogroup B, which is transmited from person to person through respiratory secretions. It may affect only the nasopharynx or it can diseminate and cause the death in a short period of time. It is estimated that 10% of the world population is asymptomatic carrier of the bacterium, but only 1% progresses to the invasive disease. The incidence of meningitis has decreased thanks in part to the conjugate vaccine for serogroup C. Since 2013 a new fourcomponent vaccine, Bexsero®, has been released and in this job we wanted to analyze the cost-effectiveness of the vaccine in Spain, the main reasons why it’s not financed and the problems created by de social alarm and lack of provision to pharmacys. After de bibliographic review os studies based in different countries of the Erupean Union, it has been concluded that the European data are not extrapolable to Spains, since the Spanish meningococcus strains are more similar to the South America strains. In addition, the social alarm created would not be justified, as there is still no evidence of the effectiveness Este trabajo tiene una finalidad docente. La Facultad de Farmacia no se hace responsable de la información contenida en el mismo. 3 of group immunity, but the availability of vaccines in hight risk situations or outbreaks is guaranteed.
Meningitis B is a severe disease caused by N. meningitids serogroup B, which is transmited from person to person through respiratory secretions. It may affect only the nasopharynx or it can diseminate and cause the death in a short period of time. It is estimated that 10% of the world population is asymptomatic carrier of the bacterium, but only 1% progresses to the invasive disease. The incidence of meningitis has decreased thanks in part to the conjugate vaccine for serogroup C. Since 2013 a new fourcomponent vaccine, Bexsero®, has been released and in this job we wanted to analyze the cost-effectiveness of the vaccine in Spain, the main reasons why it’s not financed and the problems created by de social alarm and lack of provision to pharmacys. After de bibliographic review os studies based in different countries of the Erupean Union, it has been concluded that the European data are not extrapolable to Spains, since the Spanish meningococcus strains are more similar to the South America strains. In addition, the social alarm created would not be justified, as there is still no evidence of the effectiveness Este trabajo tiene una finalidad docente. La Facultad de Farmacia no se hace responsable de la información contenida en el mismo. 3 of group immunity, but the availability of vaccines in hight risk situations or outbreaks is guaranteed.